Novo Nordisk(US:NVO) Xin Lang Cai Jing·2026-02-05 16:01Core Viewpoint - Novo Nordisk (NVO) shares fell by 6.3% following warnings about pricing pressures in the U.S. and risks associated with patent expirations [1] Group 1: Pricing Pressure and Market Competition - CEO Mike Doustdar indicated that by 2026, Novo Nordisk will face increasing pricing pressures in a competitive market [1] - The "Most Favored Nation" pricing policy promoted by former President Trump, along with the expiration of semaglutide patents in various international markets, is expected to significantly impact revenue [1] Group 2: Sales Forecast and Historical Context - The latest guidance from Novo Nordisk suggests that the company will experience its first annual sales decline in nine years, with the last occurrence being in 2017 due to a price war in the U.S. insulin market [1]